Saturday 17 October 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.48
0.07
−12.73%
Follow ONCO
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 5 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | (2.40) | (12.96) | (9.75) |
P/S ratio |
— | — | — | — | — | 0.00 | 0.64 | 1.80 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (5.72) | (30.43) | (20.98) |
Beneish M-Score |
— | — | — | — | — | — | 0.76 | 33.30 |
P/Operating CF |
— | — | — | — | — | (0.77) | (1.75) | (0.47) |
P/B ratio |
— | — | — | — | — | 2.36 | 0.19 | 0.09 |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | 0.00 | 0.43 | (4.46) |
EV/EBITDA |
— | — | — | — | — | 0.03 | 0.00 | 0.21 |
EV/Operating CF |
— | — | — | — | — | 0.08 | (0.10) | 0.38 |
EV/FCF |
— | — | — | — | — | 0.06 | (0.10) | 0.37 |
Quick Ratio |
— | 79.94 | 63.37 | 1.27 | 6.57 | 0.27 | 0.04 | 0.61 |
Current Ratio |
— | 79.94 | 66.91 | 1.88 | 6.69 | 0.34 | 0.05 | 0.66 |
Net Debt/EBITDA |
— | 6.88 | 2.66 | 0.57 | 1.91 | 0.13 | 0.01 | 0.29 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.14% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
Operating CF/Net income |
— | 0.75 | 0.80 | 0.51 | 0.64 | 0.36 | 0.18 | 0.62 |
Capex/Depreciation |
— | 0.00 | (3.81) | (0.39) | (1.37) | (8.58) | 0.00 | 0.00 |
Interest Coverage |
— | (30.20) | (71.77) | — | — | (53.65) | (40.13) | (23.78) |
| — | (20.53%) | (40.24%) | (130.89%) | (113.42%) | (314.47%) | (1,184.21%) | (127.79%) | |
| — | (36.24%) | (39.65%) | (102.44%) | (91.96%) | (65.73%) | (101.81%) | (58.49%) | |
ROIC |
— | 0.00% | (238.54%) | 0.00% | 0.00% | 0.00% | (447.13%) | (105.85%) |
Return on Tangible Assets |
— | (18.40%) | (47.53%) | (279.60%) | (60.48%) | 331.31% | 340.90% | 512.23% |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 934.03 | 3.72 | 155.28 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 3,332.31% | 6.12% | (8.11%) |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 25,249.06% | 444.99% | 863.86% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.93 | 0.96 | 0.74 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 563.76% | 17.38% | 9.11% |
Graham Net Nets |
— | — | — | — | — | (24.22) | (11.63) | (2.11) |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | (1,120.27%) | (3,337.58%) | (2,778.54%) |
Free Cash Flow Yield |
— | — | — | — | — | (594.75%) | (655.11%) | (661.95%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 585.00 | 4,206.83 | 43.37 |
Operating CF per Share |
— | (0.07) | (0.54) | (0.64) | (0.71) | (135,810.00) | (17,493.00) | (514.81) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | (61,348.00) | (47.50) | 0.00 |
Free Cash Flow per Share |
— | (0.07) | (0.54) | (0.64) | (0.71) | (197,158.00) | (17,540.50) | (514.81) |
Cash per Share |
— | 0.55 | 1.35 | 0.60 | 2.10 | 45,543.00 | 1,077.50 | 277.70 |
Shareholders Equity per Share |
— | 0.54 | 1.48 | 0.45 | 1.82 | 14,045.00 | 14,237.67 | 838.54 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.54 | 1.48 | 0.45 | 1.82 | 14,045.00 | 14,237.67 | 838.54 |
Free Cash Flow |
— | (0.83) | (1.74) | (2.05) | (8.68) | (19.72) | (10.52) | (9.68) |
Working Capital |
— | 5.98 | 4.53 | 1.44 | 22.34 | (11.35) | (17.34) | (3.07) |
Capital Expenditures |
— | 0.00 | (0.01) | 0.00 | (0.01) | (6.13) | (0.03) | — |
Net Current Asset Value |
— | 5.98 | 4.52 | 1.44 | 22.34 | (80.28) | (18.69) | (3.10) |
EV/EBIT |
— | — | — | — | — | 0.03 | 0.00 | 0.20 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 104.87 | 0.01 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.09 | 0.20 | 0.43 | 0.48 | 11.78 | 193.23 | 3.75 |
Cash ROIC |
— | (6.85%) | (19.26%) | (60.62%) | (18.04%) | (324.40%) | (114.53%) | (46.12%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 28.78 | 4.38 |
Accounts Payable Turnover |
— | 0.01 | 0.07 | 0.02 | 0.01 | 0.35 | 0.32 | 0.07 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.86 | 1.70 |
Average Days of Payables |
— | 11,193.33 | 8,088.87 | 43,397.76 | 80,477.13 | 1,630.15 | 941.10 | 3,515.40 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 112.09 | 15.93 | 300.00 |
Average Receivables |
— | 0.01 | 0.03 | 0.10 | 0.09 | 0.09 | 0.09 | 0.19 |
Average Payables |
— | 0.04 | 0.04 | 0.33 | 1.04 | 3.40 | 4.54 | 2.77 |
Average Inventory |
— | — | — | — | — | — | 0.21 | 0.11 |
Average Assets |
— | 3.04 | 5.45 | 3.95 | 14.70 | 56.91 | 57.85 | 26.55 |
Average Common Equity |
— | 5.37 | 5.37 | 3.09 | 11.92 | 11.90 | 4.97 | 12.15 |
Columns are period end dates